Mechanisms of Development of Heart Failure in Chronic Kidney Disease

Ефремова, О. А.; Камышникова, Л А; Оболонкова, Н И; Sviridova, Maria S.; Golivets, T. P.; Khamnagadaev, Igor I.

doi:10.52575/2687-0940-2022-45-3-237-252

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Они были изучены и идентифицированы в известном Фремингемском исследовании и включают возраст, мужской пол, артериальную гипертензию, сахарный диабет, гиперлипидемию, наследственность и курение [7]. В более поздних исследованиях были добавлены факторы и механизмы развития ССЗ, характерные для ХБП: воспаление, окислительный стресс, нарушение метаболизма уремических клеток, недоедание, гипергомоцистеинемия, гиперурикемия, повышение уровня лептина, дефицит карнитина, сосудистая кальцификация, гипертриглицеридемия, анемия, эндотелиальная дисфункция, быстрые изменения объема циркулирующей крови и электролитов при диализе, нарушение свертывания крови, иммуносупрессивная терапия после трансплантации почки, симпатическая гиперактивность, сердечные микрососудистые заболевания, высокий уровень конечных продуктов гликолиза, нарушенный баланс оксида азота, гипертрофия левого желудочка (ГЛЖ) [4,[7][8][9].…”

Section: факторы риска сердечнососудистых заболеванийunclassified

Biomarkers of Adverse Cardiovascular Events in Kidney Disease

Kamyshnikova,

Gorbachevskaya,

Efremova

et al. 2023

Arhivʺ vnutrennej mediciny

Self Cite

View full text Add to dashboard Cite

Based on domestic and international literature the review refers to the analysis of the research data on risk factors and biomarkers for the development of adverse cardiovascular events in patients with chronic kidney disease and acute kidney injury. Biomarker studies are important, especially in the early stages of chronic kidney disease, that is, in patients with creatinine clearance above 60 ml/min/1.73 m2, when preventive and therapeutic measures work more effectively. Among the potential predictors of adverse cardiovascular events, the biomarkers related to the following pathological processes (conditions) should be noted: oxidative stress (malondialdehyde, ischemic-modified albumin; superoxide dismutase), inflammation (interleukin-6, interleukin-18), acute kidney injury (kidney injury molecule 1; neutrophil gelatinase-associated lipocalin), cardiospecific biomarkers (highly sensitive troponin) and circulating microribonucleic acids (specific miRNA-133a, miRNA-21), as well as the prospects for further study of some biomarkers in cardionephrology are discussed. A separate emphasis is placed on the need to establish threshold values for various molecules in chronic kidney disease, depending on the degree of decline in kidney function, which will allow these indicators to be effectively used in clinical practice as diagnostic and prognostic biomarkers for cardiovascular diseases, since their usual reference values are used in the general population, will be higher in kidney disease. Currently, only for troponin and natriuretic peptides, certain reference values are established, which are less clear-cut in the population with chronic kidney disease than in the general population, and for all other biomarkers, cut-off values are not yet known.

show abstract

Section: факторы риска сердечнососудистых заболеванийunclassified

Biomarkers of Adverse Cardiovascular Events in Kidney Disease

Kamyshnikova,

Gorbachevskaya,

Efremova

et al. 2023

Arhivʺ vnutrennej mediciny

Self Cite

View full text Add to dashboard Cite

show abstract

Risk factors and diagnostic markers for acute coronary syndrome in chronic kidney disease

Kamyshnikova,

Pisankina,

Gorbachevskaya

et al. 2023

Klinicist

View full text Add to dashboard Cite

Introduction. Acute coronary artery disease is the leading cause of death in patients with chronic kidney disease (CKD). In addition, CKD itself is the initiator of acute coronary syndrome (ACS), the prevalence of which is greater, the more pronounced the impairment of kidney function and the more concomitant risk factors in the patient.Aim. To study the predictive value of various laboratory and instrumental markers in identifying the risk of developing ACS in patients with CKD.Materials and methods. A search was made for articles for the last 10 years in the databases: PubMed, Medline, Google Scholar and eLIBRARY by keywords in Russian and English, the articles were selected in accordance with the purpose of the study.Results. ACS manifests itself in CKD patients with an atypical picture, and in 3 % of cases it is generally asymptomatic. The risk of death from cardiovascular complications increases in proportion to the deterioration of the glomerular filtration rate (GFR). This progression also increases the risk of coronary artery calcification. At the same time, it was found that cystatin C is a more universal marker of a decrease in GFR than creatinine. Other laboratory markers that indicate the risk of ACS are inflammatory markers, albuminuria, troponins, natriuretic peptide.Conclusion. So far as ACS is atypical or asymptomatic, in addition to troponins and traditional instrumental diagnostic methods, markers such as GFR, albuminuria, an increase in serum cystatin C, phosphate, fibroblast growth factor-23, interleukin-6, tumor necrosis factor-alpha, total parathyroid hormone, fibrinogen, natriuretic peptide can help in its prediction.

show abstract

Mechanisms of Development of Heart Failure in Chronic Kidney Disease

Cited by 2 publications

References 0 publications

Biomarkers of Adverse Cardiovascular Events in Kidney Disease

Biomarkers of Adverse Cardiovascular Events in Kidney Disease

Risk factors and diagnostic markers for acute coronary syndrome in chronic kidney disease

Contact Info

Product

Resources

About